
    
      OUTLINE:

      Patients receive ixazomib citrate orally (PO) on days 1, 8 ,15, and 22. Cycles repeat every
      28 days in the absence of disease progression or unacceptable toxicity. Upon completion of 6
      cycles of ixazomib citrate therapy, patients also receive rituximab intravenously (IV) once
      weekly for 4 doses total, followed by ixazomib citrate alone, until disease progression or
      unacceptable toxicity.

      After completion of study treatment, patients are followed up at 30 days and then every 3
      months for 3 years.
    
  